BACKGROUND AND PURPOSE: The aims of the present work were to study the mechanism of the reverse rate dependency of different interventions prolonging cardiac action potential duration (APD). EXPERIMENTAL APPROACH: The reverse rate-dependent lengthening effect of APD-prolonging interventions and the possible involvement of I(Kr) (rapid component of the delayed rectifier potassium current) and I(K1) (inward rectifier potassium current) were studied by using the standard microelectrode and the whole-cell patch-clamp techniques in dog multicellular ventricular preparations and in myocytes isolated from undiseased human and dog hearts. KEY RESULTS: All applied drugs--dofetilide (1 micromol.L(-1)), BaCl(2) (10 micromol.L(-1)), BAY-K-8644 (1 micromol.L(-1)), veratrine (1 microg.mL(-1))--lengthened APD in a reverse rate-dependent manner regardless of their mode of action, suggesting that reverse rate dependency may not represent a specific mechanism of APD prolongation. The E-4031-sensitive current (I(Kr)) and the Ba(2+)-sensitive current (I(K1)) were recorded during repolarizing voltage ramps having various steepness and also during action potential waveforms with progressively prolonged APD. Gradually delaying repolarization results in smaller magnitude of I(Kr) and I(K1) currents at an isochronal phase of the pulses. This represents a positive feedback mechanism, which appears to contribute to the reverse rate-dependent prolongation of action potentials. CONCLUSIONS AND IMPLICATIONS: Action potential configuration may influence the reverse rate-dependent APD prolongation due to the intrinsic properties of I(Kr) and I(K1) currents. Drugs lengthening repolarization by decreasing repolarizing outward, or increasing depolarizing inward, currents are expected to cause reverse rate-dependent APD lengthening with high probability, regardless of which current they modify.
BACKGROUND AND PURPOSE: The aims of the present work were to study the mechanism of the reverse rate dependency of different interventions prolonging cardiac action potential duration (APD). EXPERIMENTAL APPROACH: The reverse rate-dependent lengthening effect of APD-prolonging interventions and the possible involvement of I(Kr) (rapid component of the delayed rectifier potassium current) and I(K1) (inward rectifier potassium current) were studied by using the standard microelectrode and the whole-cell patch-clamp techniques in dog multicellular ventricular preparations and in myocytes isolated from undiseased human and dog hearts. KEY RESULTS: All applied drugs--dofetilide (1 micromol.L(-1)), BaCl(2) (10 micromol.L(-1)), BAY-K-8644 (1 micromol.L(-1)), veratrine (1 microg.mL(-1))--lengthened APD in a reverse rate-dependent manner regardless of their mode of action, suggesting that reverse rate dependency may not represent a specific mechanism of APD prolongation. The E-4031-sensitive current (I(Kr)) and the Ba(2+)-sensitive current (I(K1)) were recorded during repolarizing voltage ramps having various steepness and also during action potential waveforms with progressively prolonged APD. Gradually delaying repolarization results in smaller magnitude of I(Kr) and I(K1) currents at an isochronal phase of the pulses. This represents a positive feedback mechanism, which appears to contribute to the reverse rate-dependent prolongation of action potentials. CONCLUSIONS AND IMPLICATIONS: Action potential configuration may influence the reverse rate-dependent APD prolongation due to the intrinsic properties of I(Kr) and I(K1) currents. Drugs lengthening repolarization by decreasing repolarizing outward, or increasing depolarizing inward, currents are expected to cause reverse rate-dependent APD lengthening with high probability, regardless of which current they modify.
Authors: L Virág; N Iost; M Opincariu; J Szolnoky; J Szécsi; G Bogáts; P Szenohradszky; A Varró; J G Papp Journal: Cardiovasc Res Date: 2001-03 Impact factor: 10.787
Authors: A Varro; B Baláti; N Iost; J Takács; L Virág; D A Lathrop; L Csaba; L Tálosi; J G Papp Journal: J Physiol Date: 2000-02-15 Impact factor: 5.182
Authors: András Varró; Péter Biliczki; Norbert Iost; László Virág; Ottó Hála; Péter Kovács; Péter Mátyus; Julius Gy Papp Journal: Curr Med Chem Date: 2004-01 Impact factor: 4.530
Authors: Milan Stengl; Paul G A Volders; Morten B Thomsen; Roel L H M G Spätjens; Karin R Sipido; Marc A Vos Journal: J Physiol Date: 2003-06-20 Impact factor: 5.182
Authors: Haibo Ni; Alex Fogli Iseppe; Wayne R Giles; Sanjiv M Narayan; Henggui Zhang; Andrew G Edwards; Stefano Morotti; Eleonora Grandi Journal: Br J Pharmacol Date: 2020-08-09 Impact factor: 8.739
Authors: Lin Wu; Jihua Ma; Hong Li; Chao Wang; Eleonora Grandi; Peihua Zhang; Antao Luo; Donald M Bers; John C Shryock; Luiz Belardinelli Journal: Circulation Date: 2011-04-11 Impact factor: 29.690
Authors: Tamás Árpádffy-Lovas; István Baczkó; Beáta Baláti; Miklós Bitay; Norbert Jost; Csaba Lengyel; Norbert Nagy; János Takács; András Varró; László Virág Journal: Front Pharmacol Date: 2020-04-30 Impact factor: 5.810
Authors: Attila Kristóf; Zoltán Husti; István Koncz; Zsófia Kohajda; Tamás Szél; Viktor Juhász; Péter Biliczki; Norbert Jost; István Baczkó; Julius Gy Papp; András Varró; László Virág Journal: PLoS One Date: 2012-12-31 Impact factor: 3.240
Authors: Bradley J Ridder; Derek J Leishman; Matthew Bridgland-Taylor; Mohammadreza Samieegohar; Xiaomei Han; Wendy W Wu; Aaron Randolph; Phu Tran; Jiansong Sheng; Timm Danker; Anders Lindqvist; Daniel Konrad; Simon Hebeisen; Liudmila Polonchuk; Evgenia Gissinger; Muthukrishnan Renganathan; Bryan Koci; Haiyang Wei; Jingsong Fan; Paul Levesque; Jae Kwagh; John Imredy; Jin Zhai; Marc Rogers; Edward Humphries; Robert Kirby; Sonja Stoelzle-Feix; Nina Brinkwirth; Maria Giustina Rotordam; Nadine Becker; Søren Friis; Markus Rapedius; Tom A Goetze; Tim Strassmaier; George Okeyo; James Kramer; Yuri Kuryshev; Caiyun Wu; Herbert Himmel; Gary R Mirams; David G Strauss; Rémi Bardenet; Zhihua Li Journal: Toxicol Appl Pharmacol Date: 2020-03-21 Impact factor: 4.219